Key Takeaways
- Wall Street analysts project an average price of $89.36 for RKLB, suggesting approximately 33% upside potential
- The company secured a $190M U.S. Department of Defense contract for hypersonic testing, driving its backlog beyond $2 billion
- Clear Street began coverage with a Buy recommendation and $88 target price
- Neutron rocket hardware is complete and awaiting final assembly, with first flight scheduled for Q4 2026
- Company insiders have divested more than $136M in shares over the past three months, sparking dilution questions
Rocket Lab (RKLB) has retreated approximately 6.5% in recent trading sessions, now changing hands at $67.23. Yet analysts remain optimistic about the company’s trajectory.
Wall Street’s consensus price target stands at $89.36 — representing roughly 33% appreciation from current trading levels. The stock carries nine Buy ratings alongside four Hold recommendations.
The recent weakness contradicts several encouraging company developments. Broader aerospace and defense sector pressure, driven by escalating Middle East geopolitical uncertainty, has weighed on RKLB shares in the near term.
The most significant recent announcement involves a $190 million U.S. Department of Defense award. This agreement covers up to 20 HASTE hypersonic test missions — marking the largest launch contract ever awarded to Rocket Lab. Chief Executive Sir Peter Beck described it as “a proud moment” for the organization.
This defense contract elevated Rocket Lab’s cumulative backlog above $2 billion. This substantial order book represents a robust revenue pipeline for upcoming quarters.
Additionally, Rocket Lab executed its 84th Electron mission — marking the 8th flight for Japanese customer Synspective. This successful deployment underscores the company’s reliable launch rhythm and enduring partnerships with constellation operators.
Neutron Development Progresses Toward Inaugural Flight
The Neutron launch vehicle represents Rocket Lab’s most significant long-term growth driver. The 43-meter partially reusable rocket targets satellite constellation deployments and cargo transportation missions. This positions Rocket Lab as a direct competitor to SpaceX’s Falcon 9 platform.
Critical hardware elements — including the distinctive “Hungry Hippo” payload fairing and primary thrust structure — have completed manufacturing and await final integration. The maiden launch is targeted for Q4 2026, following a minor manufacturing-related schedule adjustment.
Clear Street’s Gregory Pendy recently launched coverage with a Buy rating and $88 price objective. He highlighted Rocket Lab’s vertically integrated manufacturing strategy as a competitive advantage, projecting Electron launch frequency to reach approximately 52 annual missions by 2030.
Cantor Fitzgerald’s Andres Sheppard maintained his Buy rating with an $85 target, identifying the inaugural Neutron flight as the most critical near-term catalyst for share performance.
Executive Divestments Draw Investor Attention
However, not all indicators point upward. Company executives have been reducing their holdings. Chief Financial Officer Adam Spice divested 62,744 shares at $69.59 in early March, representing a 4.61% reduction in his position. Director Frank Klein subsequently sold 36,768 shares at $71.95.
Cumulatively, company insiders have liquidated over 1.81 million shares valued at approximately $136.5 million during the past 90 days. This selling activity has drawn scrutiny from investors monitoring potential dilution risks, particularly following a recent equity offering.
Institutional investor behavior tells a contrasting story. Swiss Life Asset Management expanded its holdings by 480.9%, acquiring 48,369 additional shares. AQR Capital Management increased its position by 114%. Institutional investors collectively control 71.78% of outstanding shares.
Morgan Stanley elevated RKLB from Equal Weight to Overweight in January, raising its price objective to $105. Needham maintains a Buy rating with a $95 target. Zacks transitioned to a Hold rating in February.
RKLB has traded between $14.71 and $99.58 over the past 52 weeks. The stock’s 50-day moving average currently sits at $76.31.
